Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BYSI)

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

GlobeNewswire 2 days ago

BeyondSpring Files 2023 Annual Report on Form 20-F

GlobeNewswire 2 days ago

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

GlobeNewswire March 25, 2024

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements

GlobeNewswire February 26, 2024

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

GlobeNewswire January 10, 2024

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

GlobeNewswire December 18, 2023

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

GlobeNewswire November 7, 2023

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin's Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models

GlobeNewswire October 31, 2023

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire October 30, 2023
View More News ››

Opinion & Analysis (NDAQ:BYSI)

Biotech advances potential 'billion-dollar drug' with new trial launch in China

Streetwise Reports December 8, 2017
View More Opinion ››

Bullboard Posts (NDAQ:BYSI)

RE:REAL DEAL

From last quarterly report:  "As of September 30, 2021, the Company had cash, cash equivalents, and short-term investments of ...
dmacd - March 14, 2022

RE:Compelling despite Headwinds

Well if it goes to $3/sh or cash valuation then it is time for me to double down. I did not think that chance would come. The market is...
dmacd - January 19, 2022

Compelling despite Headwinds

$90M cash vs $128M MC. Way too low for a company this advanced. FDA caused job losses in US with their approach. Would be nice to get...
dmacd - January 12, 2022

RE:REAL DEAL

Blockbuster is probable. Strongest terms with a Chinese entity I have seen in quite some time for an emerging player. $45M cash up front...
dmacd - August 26, 2021

REAL DEAL

disruptive lung cancer treatment on verge of FDA approval
Felix12345 - August 23, 2021
View more Bullboard ››

Lucky Minerals Inc

Lucky Minerals Inc

Lucky Minerals Inc. is a Canada-based exploration and development company. The Company owns a 100% interest in the Fortuna ...
View More »